Polymeric nanoparticles loaded with the 3,5,3 '-triiodothyroacetic acid (Triac), a thyroid hormone: factorial design, characterization, and release kinetics

被引:36
|
作者
dos Santos, Karen C. [1 ]
da Silva, Maria Fatima G. F. [1 ]
Pereira-Filho, Edenir R. [1 ]
Fernandes, Joao B. [1 ]
Polikarpov, Igor [2 ]
Forim, Moacir R. [1 ]
机构
[1] Univ Fed Sao Carlos, Dept Chem, Km 235,POB 676, BR-13565905 Sao Carlos, SP, Brazil
[2] Univ Sao Paulo, Phys Inst Sao Carlos, Sao Carlos, SP, Brazil
来源
NANOTECHNOLOGY SCIENCE AND APPLICATIONS | 2012年 / 5卷
基金
巴西圣保罗研究基金会;
关键词
Triac; nanoparticles; optimization; factorial design of experiments; HPLC analytical method;
D O I
10.2147/NSA.S32837
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
This present investigation deals with the development and optimization of polymeric nanoparticle systems loaded with 3,5,3'-triiodothyroacetic acid (Triac). A 211-6 fractional factorial design and another 22 factorial design were used to study the contrasts on particle size distribution, morphology, surface charge, drug content, entrapment efficiency, and in vitro drug release profiles. The independent variables were the concentration of Triac, type and quantity of both polymer and oil, quantity of Span (TM) 60 and Tween (R) 80, volume of solvent and water, and velocity of both magnetic stirring and the transfer of the organic phase into the aqueous solution. The results of optimized formulations showed a narrow size distribution with a polydispersity index lower than 0.200. The particle sizes were on average 159.6 nm and 285.6 nm for nanospheres and nanocapsules, respectively. The zeta potential was higher than 20 mV (in module) and the entrapment efficiency was nearly 100%. A high-performance liquid chromatography method was developed, validated, and efficiently applied to Triac quantification in colloidal suspension. The main independent variables were the type and quantity of the polymer and oil. In vitro drug release profile depicted several features to sustain Triac release. Different formulations showed various release rates indicating an interaction between Triac and other formulation compounds such as polymer and/or oil quantity. Two different models were identified (biexponential and monoexponential) that allowed the control of both the release rate and Triac concentration. Thus, the prepared nanoparticles described here may be of clinical importance in delivering Triac for thyroid treatment.
引用
收藏
页码:37 / 48
页数:12
相关论文
共 50 条
  • [1] THYROID HORMONE RESISTANCE: TRIAC (3,5,3′-TRIIODOTHYROACETIC ACID) EXPERIENCE
    Ugurlu, Aylin Kilinc
    Doger, Esra
    Akbas, Emine Demet
    Bideci, Aysun
    Camurdan, Orhun
    Cinaz, Peyami
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 593 - 593
  • [2] 3,5,3'-TRIIODOTHYROACETIC ACID (TRIAC) THERAPY FOR THYROID-HORMONE RESISTANCE
    KUNITAKE, JM
    HARTMAN, N
    ERIKSEN, EM
    LEBRON, BA
    HERSHMAN, JM
    CLINICAL RESEARCH, 1988, 36 (01): : A124 - A124
  • [3] Successful therapy with 3,5,3'-triiodothyroacetic acid (TRIAC) in pituitary resistance to thyroid hormone
    Darendeliler, F
    Bas, F
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1997, 10 (05): : 535 - 538
  • [4] Development and validation of a fast RP-HPLC method to determine the analogue of the thyroid hormone, 3,5,3′-triiodothyroacetic acid (TRIAC), in polymeric nanoparticles
    dos Santos, Karen C.
    da Silva, Maria Fatima G. F.
    Fernandes, Joao B.
    Vieira, Paulo C.
    Polikarpov, Igor
    Zucolotto, Valtencir
    Forim, Moacir R.
    ANALYTICAL METHODS, 2011, 3 (09) : 1936 - 1942
  • [5] 3,5,3'-TRIIODOTHYROACETIC ACID THERAPY FOR THYROID-HORMONE RESISTANCE
    KUNITAKE, JM
    HARTMAN, N
    HENSON, LC
    LIEBERMAN, J
    WILLIAMS, DE
    WONG, M
    HERSHMAN, JM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (02): : 461 - 466
  • [6] Differences in response of thyrotropin to 3,5,3'-triiodothyronine and 3,5,3'-triiodothyroacetic acid in patients with resistance to thyroid hormone
    Ueda, S
    Takamatsu, J
    Fukata, S
    Tanaka, K
    Shimizu, N
    Sakata, S
    Yamaji, T
    Kuma, K
    Ohsawa, N
    THYROID, 1996, 6 (06) : 563 - 570
  • [7] 3,5,3-TRIIODOTHYROACETIC ACID (TRIAC) EFFECTS ON PITUITARY THYROID REGULATION AND ON PERIPHERAL TISSUE PARAMETERS
    LIND, P
    LANGSTEGER, W
    KOLTRINGER, P
    EBER, O
    NUKLEARMEDIZIN, 1989, 28 (06) : 217 - 220
  • [8] EFFECTS OF 3,5,3'-TRIIODOTHYROACETIC ACID (TRIAC) ON THE PROTEIN-METABOLISM IN OBESE AND NONOBESE ZUCKER RATS
    DUMAS, P
    AUTISSIER, N
    LOIREAU, A
    MICHEL, R
    COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES, 1982, 176 (02): : 178 - 183
  • [9] 3,3′,5-Triiodothyroacetic acid (TRIAC) induces embryonic ζ-globin expression via thyroid hormone receptor α
    Chen, Huiqiao
    Wang, Zixuan
    Yu, Shanhe
    Han, Xiao
    Deng, Yun
    Wang, Fuhui
    Chen, Yi
    Liu, Xiaohui
    Zhou, Jun
    Zhu, Jun
    Yuan, Hao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [10] 3,3′,5-Triiodothyroacetic acid (TRIAC) induces embryonic ζ-globin expression via thyroid hormone receptor α
    Huiqiao Chen
    Zixuan Wang
    Shanhe Yu
    Xiao Han
    Yun Deng
    Fuhui Wang
    Yi Chen
    Xiaohui Liu
    Jun Zhou
    Jun Zhu
    Hao Yuan
    Journal of Hematology & Oncology, 14